Kadimastem Ltd.

Kadimastem Ltd. company information, Employees & Contact Information

Explore related pages

Kadimastem Ltd. email format Kadimastem Ltd. management contacts

Related company profiles:

Kadimastem (TASE:KDST) A clinical stage biotech company introducing a cutting-edge TECHNOLOGY PLATFORM for the Development, Manufacturing, and Bio-Banking of functional human cells, providing OFF-THE-SHELF TREATMENT for multiple indications featuring ALS and Type 1 Diabetes as our top two leading projects.

Company Details

Employees
30
Founded
-
Address
Pinhas Sapir 7, Nes Ziona,israel 74140,israel
Phone
97297289100698
Email
in****@****tem.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Website
kadimastem.com
Keywords
stem cells, drug screening for myelin sheath, human oligodendrocytes, human beta cells, bio-banking, cell therapy, GMP facilities, cell production, type 1 diabetes, ALS, ALStreatment, DiabetesCURE, Clinicaltrials.
HQ
Nes Ziona, Israel
Competitors
AlloVir, Ascendis Pharma, uniQure, BiomX (NYSE: PHGE), Beam Therapeutics, NLS Pharmaceutics AG, Viking Therapeutics, Inc., Brainstorm Cell Therapeutics, Kalaris Therapeutics, Neurogene Inc..
Looking for a particular Kadimastem Ltd. employee's phone or email?

Kadimastem Ltd. Questions

News

NLS Pharmaceutics and Kadimastem Announce Strategic Collaboration between Kadimastem and TargetGene to Advance Next-Generation Gene-Edited Cell Therapies - PR Newswire

NLS Pharmaceutics and Kadimastem Announce Strategic Collaboration between Kadimastem and TargetGene to Advance Next-Generation Gene-Edited Cell Therapies PR Newswire

NLS and Kadimastem Announce Receipt of Nasdaq Approval; Merger Expected to Close on October 30, 2025 - Sahm

NLS and Kadimastem Announce Receipt of Nasdaq Approval; Merger Expected to Close on October 30, 2025 Sahm

NLS Pharma (NASDAQ: NLSP) and Kadimastem secure Nasdaq listing; NewcelX to trade as NCEL - Stock Titan

NLS Pharma (NASDAQ: NLSP) and Kadimastem secure Nasdaq listing; NewcelX to trade as NCEL Stock Titan

NLS Pharmaceutics Shareholders Approve Merger with Kadimastem and Related Proposals at Extraordinary General Meeting - PR Newswire

NLS Pharmaceutics Shareholders Approve Merger with Kadimastem and Related Proposals at Extraordinary General Meeting PR Newswire

84.4% Ownership Stake: Kadimastem-NLS Pharma Merger Creates NewCelX with ALS and Diabetes Pipeline - Stock Titan

84.4% Ownership Stake: Kadimastem-NLS Pharma Merger Creates NewCelX with ALS and Diabetes Pipeline Stock Titan

Kadimastem and NLS Pharmaceutics Announce Effectiveness of SEC Registration Statement in Connection with Proposed Merger - PR Newswire

Kadimastem and NLS Pharmaceutics Announce Effectiveness of SEC Registration Statement in Connection with Proposed Merger PR Newswire

NLS Pharmaceutics and Kadimastem announce a Hong Kong Patent Covering Cell-Selection and Enrichment Technology for IsletRx for Diabetes Patients - PR Newswire

NLS Pharmaceutics and Kadimastem announce a Hong Kong Patent Covering Cell-Selection and Enrichment Technology for IsletRx for Diabetes Patients PR Newswire

NLS Pharmaceutics Approve Merger with Kadimastem - citybiz

NLS Pharmaceutics Approve Merger with Kadimastem citybiz

Kadimastem and NLS Pharmaceutics Merger Update - citybiz

Kadimastem and NLS Pharmaceutics Merger Update citybiz

NLS Pharmaceutics Highlights Continued Progress in iTOL-102 Diabetes Program as BIRD Foundation Approves Additional Milestone Payment to Kadimastem and iTolerance for Continued Co-Development of Type 1 Diabetes Cell Therapy - PR Newswire

NLS Pharmaceutics Highlights Continued Progress in iTOL-102 Diabetes Program as BIRD Foundation Approves Additional Milestone Payment to Kadimastem and iTolerance for Continued Co-Development of Type 1 Diabetes Cell Therapy PR Newswire

NLS Pharmaceutics and Kadimastem Announce Pricing and Closing of $1 Million Equity Financing - PR Newswire

NLS Pharmaceutics and Kadimastem Announce Pricing and Closing of $1 Million Equity Financing PR Newswire

NLS Pharmaceutics Raises $3M at Premium for Game-Changing Merger: ALS and Diabetes Trials Next - Stock Titan

NLS Pharmaceutics Raises $3M at Premium for Game-Changing Merger: ALS and Diabetes Trials Next Stock Titan

NLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement - Yahoo Finance

NLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement Yahoo Finance

NLS Pharmaceutics CEO Issues Letter to Shareholders - PR Newswire

NLS Pharmaceutics CEO Issues Letter to Shareholders PR Newswire

Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment - PR Newswire

Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment PR Newswire

Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics - PR Newswire

Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics PR Newswire

NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Filing of F-4 Registration Statement with the SEC Ahead of Proposed Merger - PR Newswire

NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Filing of F-4 Registration Statement with the SEC Ahead of Proposed Merger PR Newswire

NLS Pharmaceutics and Kadimastem Unveil Multi-Target Approach to Diabetes, Expanding Beyond GLP-1 Therapies - PR Newswire

NLS Pharmaceutics and Kadimastem Unveil Multi-Target Approach to Diabetes, Expanding Beyond GLP-1 Therapies PR Newswire

NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce the Initial Closing of $500,000 of the Previously Announced $1 Million Fundraising by NLS Following its Extraordinary General Meeting at a Share Price of $3.10, Representing 48% Above the Market S - PR Newswire

NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce the Initial Closing of $500,000 of the Previously Announced $1 Million Fundraising by NLS Following its Extraordinary General Meeting at a Share Price of $3.10, Representing 48% Above the Market S PR Newswire

Strategic Biotech Merger: NLS Pharmaceutics and Kadimastem Unite to Transform Neurodegenerative Treatment - Stock Titan

Strategic Biotech Merger: NLS Pharmaceutics and Kadimastem Unite to Transform Neurodegenerative Treatment Stock Titan

NLS Pharmaceutics and Kadimastem Enter into a Definitive Merger Agreement - ACCESS Newswire

NLS Pharmaceutics and Kadimastem Enter into a Definitive Merger Agreement ACCESS Newswire

Companies like Kadimastem Ltd.

NLS Pharmaceutics AG logo - Similar company to Kadimastem Ltd.

Nls Pharmaceutics Ag

6
Neurogene Inc. logo - Similar company to Kadimastem Ltd.

Neurogene Inc.

107
Kalaris Therapeutics logo - Similar company to Kadimastem Ltd.

Kalaris Therapeutics

13
Ascendis Pharma logo - Similar company to Kadimastem Ltd.

Ascendis Pharma

1.19K
Brainstorm Cell Therapeutics logo - Similar company to Kadimastem Ltd.

Brainstorm Cell Ther...

32
Beam Therapeutics logo - Similar company to Kadimastem Ltd.

Beam Therapeutics

557
Viking Therapeutics, Inc. logo - Similar company to Kadimastem Ltd.

Viking Therapeutics,...

43
uniQure logo - Similar company to Kadimastem Ltd.

Uniqure

311
BiomX (NYSE: PHGE) logo - Similar company to Kadimastem Ltd.

Biomx (Nyse: Phge)

64
AlloVir logo - Similar company to Kadimastem Ltd.

Allovir

17

Top Kadimastem Ltd. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant